<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Galani, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized trials of adjuvant and neoadjuvant chemotherapy in bladder cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Seminars in Urologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adjuvant</style></keyword><keyword><style  face="normal" font="default" size="100%">Bladder cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoadjuvant chemotherapy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2001</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035108854&amp;partnerID=40&amp;md5=951dea17f62c86f585b7398a9892a535</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">59 - 65</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Data of randomized studies of adjuvant and neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer were reviewed. Four adjuvant studies have been published. The interpretation of their data is compromised primarily because of small patient numbers. Thus, a possible survival advantage cannot be documented, and significantly larger, prospective studies are needed. However, there is some evidence of improved disease-free survival for patients with non-organ-confined tumors treated with cisplatin-based combination chemotherapy. More data are available for neoadjuvant chemotherapy. The already published randomized studies, including a large trial of who was designed to detect a 10% survival benefit, do not indicate a significant advantage for neoadjuvant chemotherapy. Radical cystectomy remains the standard treatment to which other therapeutic modalities must be compared. Copyright © 2001 by W.B. Saunders Company.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :4Export Date: 21 February 2017</style></notes></record></records></xml>